NCT03815383UnknownPhase 1
A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University1 site in 1 country12 target enrollmentStarted: April 11, 2019Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Safety:TEAEs
Study Overview
Brief Summary
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
Detailed Description
The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Volunteered to participate in this study and signed informed consent.
- •Age 18-75 years old, male or female.
- •Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG diagnostic criteria 2014).
- •Patients with relapsed or refractory multiple myeloma.
- •Subjects have one or more measurable multiple myeloma lesion, must include one of the following conditions:
- •Serum M protein≥1 g/dl(10g/L)
- •Urine M protein≥200 mg/24h
- •Serum free light chain(sFLC): κ/λ ratio abnormal and ≥10 mg/dl
- •Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
- •At least 2 weeks from monoclonal antibody therapy prior to CAR T cell therapy.
- •ECOG scores 0 -
- •Normal cardiac diastolic function, left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography), no serious arrhythmia.
- •No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92% on room air.
- •No contraindications of leukapheresis.
- •Expected survival > 12 weeks.
- •Female subjects in childbearing age, their serum or urine pregnancy test must be negative,until 7 days before cell therapy and all subjects must agree to take effective contraceptive measures during the trial.
Exclusion Criteria
- •Have a history of allergy to cellular products.
- •Any kind of these laboratory testing: including but not limited to,serum total bilirubin≧1.5mg/dl, serum ALT, AST≧2.5×ULN, serum creatinine≧2.0mg/dl, Hb (hemoglobin)<80g/L, neutrophils<1000/mm^3, platelets≦50000/mm^3 or platelet count maintained by transfusion.
- •Subjects with the clinically significant cardiovascular diseases.
- •A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral ischemia or hemorrhagic disease.
- •Use any anticoagulant (except aspirin).
- •Patients requiring urgent treatment due to tumor progression or spinal cord compression.
- •Patients with active CNS involvement or clinical syndrome of MM meningeal involvement.
- •After allogeneic hematopoietic stem cell transplantation.
- •Plasma cell leukemia.
- •Subjects with any autoimmune disease or any immune deficiency disease or other disease in need of immunosuppressive therapy.
- •Uncontrolled active infection.
- •Prior treatment with CAR T therapy or any other genetically modified T cell therapy.
- •Live vaccine inoculation within four weeks before enrollment.
- •Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons.
- •Have a history of alcoholism, drug addiction and mental illness.
- •Participated in any other clinical trial within one month.
- •The investigators believe that there are other circumstances that are not suitable for the trial.
Arms & Interventions
C-CAR088
Experimental
Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
Intervention: C-CAR088 (Biological)
Outcomes
Primary Outcomes
Safety:TEAEs
Time Frame: 30 days
The incidence of treatment-emergent adverse events (TEAEs)
Secondary Outcomes
- ORR(12 months)
- PFS(6 months, 12 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaMultiple MyelomaNCT04322292Institute of Hematology & Blood Diseases Hospital, China9
Recruiting
Phase 1
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid TumorsProtein Kinase InhibitorsOther Protocol Specified CriteriaLung NeoplasmsBrain NeoplasmsNCT06128148Guangzhou JOYO Pharma Co., Ltd101
Terminated
Phase 1
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid TumorsSolid TumorColorectal CancerNCT04696848Tae Won Kim25
Recruiting
Phase 1
NV-001 in the Treatment of Advanced Solid TumorsMalignant NeoplasmNCT06051760Cancer Institute and Hospital, Chinese Academy of Medical Sciences20
Completed
Phase 1
A Single-dose Study of Octreotide Injection in Healthy Adult SubjectsAcromegalyNCT05761431CSPC ZhongQi Pharmaceutical Technology Co., Ltd.56